Intravascular Iliac Artery Lithotripsy to Facilitate Aortic Endograft Delivery: Midterm Results of a Dual-Center Experience.

abdominal endovascular aortic repair aorto-iliac occlusive disease calcified iliac hostile access iliac conduit intravascular lithotripsy large-bore devices paving and cracking thoracic endovascular aortic repair vessel compliance

Journal

Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists
ISSN: 1545-1550
Titre abrégé: J Endovasc Ther
Pays: United States
ID NLM: 100896915

Informations de publication

Date de publication:
01 Apr 2024
Historique:
medline: 2 4 2024
pubmed: 2 4 2024
entrez: 2 4 2024
Statut: aheadofprint

Résumé

To assess the feasibility and safety of intravascular lithotripsy (IVL) for enabling transfemoral abdominal (EVAR), thoracic (TEVAR), and thoracoabdominal (BEVAR) endovascular aneurysm repair in patients with narrow and calcified iliac arteries. Consecutive patients treated with IVL for severe calcified and narrowed iliac access before EVAR, TEVAR, or BEVAR between November 2020 and June 2022 were retrospectively evaluated. All anatomical iliac characteristics were acquired by multi-planar reconstruction of preoperative computed tomography angiography (CTA). The hostility of the vascular accesses was classified based on Peripheral Arterial Calcium Scoring System (PACSS) and calcified access severity score (CASS), a new score considering both anatomical (calcium grade and length, minimum lumen diameter [MLD], and tortuosity index) and aortic stent-graft (SG/MLD index) parameters. Primary endpoint was technical success defined as successful aortic endograft delivery and deployment without iliac rupture. Freedom from complications and primary patency were additionally analyzed. Twenty-eight iliac axes were treated with IVL (8 bilateral) in 20 patients (mean age 74.5±6.7 years) with a mean follow-up of 26.5±6.2 (range 17-36) months. Ten patients underwent EVAR: 3 TEVAR, and 7 BEVAR procedures. In 14 patients (70%), aneurysm disease was associated with symptomatic aorto-iliac occlusive disease (AIOD), with Rutherford class III to IV. The PACSS was grade IV in 89% of the cases and the CASS (mean 14±2) was grade III to IV in all cases. The stent-graft (SG) outer diameter (5.60±1.65 mm) was significantly larger by 50% than MLD (3.96±1.20 mm), with an SG/MLD index of 1.50±0.51 (p<0.001). Technical success was 100%. No dissection, rupture, or distal embolization occurred. One (3.4%) bail-out stenting was necessary as endoconduit after IVL treatment. One month CTA showed that postoperative luminal gain increased by 93% (p<0.001). An improvement of 2 Rutherford classes occurred in all AIOD patients with a primary patency of 100% at last follow-up. This study shows the safety and feasibility of IVL as a valuable option to treat narrow and calcified iliac arteries to facilitate endograft delivery. Further studies will be useful to confirm these results. In this article, the use of intravascular iliac artery lithotripsy to facilitate aortic endograft delivery is explored. The presence of iliac severe calcifications still represents a contraindication for aortic endovascular repair. Intravascular lithotripsy increases the feasibility and safety of endovascular aortic procedures, facilitating endograft delivery and reducing the risk of iliac rupture and/or dissections by improving vessel compliance and luminal gain. This novel vessel preparation could be an alternative to "paving and cracking" and/or iliac conduits. This study describes a new score to classify the severity of iliac calcifications, considering anatomical parameters and the profile of aortic endografts delivery system.

Identifiants

pubmed: 38561973
doi: 10.1177/15266028241241246
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

15266028241241246

Déclaration de conflit d'intérêts

Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Stefano Fazzini and Michel Joseph Bosiers have a consulting agreement with Shockwave Medical.

Auteurs

Stefano Fazzini (S)

Vascular and Endovascular Surgery, Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy.

Federico Francisco Pennetta (FF)

Vascular and Endovascular Surgery, Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy.

Giovanni Torsello (G)

Institute for Vascular Research, St. Franziskus-Hospital, Münster, Germany.

Valerio Turriziani (V)

Vascular and Endovascular Surgery, Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy.

Simona Vona (S)

Vascular and Endovascular Surgery, Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy.

Andrea Ascoli Marchetti (A)

Vascular and Endovascular Surgery, Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy.

Arnaldo Ippoliti (A)

Vascular and Endovascular Surgery, Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy.

Martin Austermann (M)

Department of Vascular Surgery, St. Franziskus-Hospital, Münster, Germany.

Michel Joseph Bosiers (MJ)

Department of Vascular Surgery, St. Franziskus-Hospital, Münster, Germany.
Department of Vascular Surgery, University Hospital Bern, University of Bern, Bern, Switzerland.

Classifications MeSH